Myeloid Cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice

Journal of Immunology

Volumn 194, Issue 1, 2015, Pages 334-348

  Lalani, Almin I ^a   Moore, Carissa R ^a   Luo, Chang ^a   Kreider, Benjamin Z ^a   Liu, Yan ^a   Morse, Herbert C ^b   Xie, Ping ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; I KAPPA B2; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CELL CULTURE; CELL MATURATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IN VIVO STUDY; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL TRANSFORMATION; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYTOKINES; ENZYME ACTIVATION; IMMUNOGLOBULIN G; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; NEUTROPHILS; NF-KAPPA B P52 SUBUNIT; POLY I-C; T-LYMPHOCYTES; TNF RECEPTOR-ASSOCIATED FACTOR 3; TOLL-LIKE RECEPTOR 4;

EID: 84919683907     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401548     Document Type: Article

References (89)

1. Xie, P. 2013. TRAF molecules in cell signaling and in human diseases. J. Mol. Signal. 8: 7.
2. Häcker, H., P. H. Tseng, and M. Karin. 2011. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat. Rev. Immunol. 11: 457-468.
3. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11: 373-384.
4. Saleh, M. 2011. The machinery of Nod-like receptors: Refining the paths to immunity and cell death. Immunol. Rev. 243: 235-246.
5. Yu, M., and S. J. Levine. 2011. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to doublestranded RNA viruses. Cytokine Growth Factor Rev. 22: 63-72.
6. Xu, Y., G. Cheng, and D. Baltimore. 1996. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 5: 407-415.
7. Xie, P., L. L. Stunz, K. D. Larison, B. Yang, and G. A. Bishop. 2007. Tumor necrosis factor receptor-Associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 27: 253-267.
8. Moore, C. R., Y. Liu, C. Shao, L. R. Covey, H. C. Morse, III, and P. Xie. 2012. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia 26: 1122-1127.
9. Gardam, S., F. Sierro, A. Basten, F. Mackay, and R. Brink. 2008. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28: 391-401.
10. Xie, P., Z. J. Kraus, L. L. Stunz, Y. Liu, and G. A. Bishop. 2011. TNF receptorassociated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling. J. Immunol. 186: 143-155.
11. Chang, J. H., H. Hu, J. Jin, N. Puebla-Osorio, Y. Xiao, B. E. Gilbert, R. Brink, S. E. Ullrich, and S. C. Sun. 2014. TRAF3 regulates the effector function of regulatory T cells and humoral immune responses. J. Exp. Med. 211: 137-151.
12. Yi, Z., L. L. Stunz, and G. A. Bishop. 2013. TNF receptor associated factor 3 plays a key role in development and function of invariant natural killer T cells. J. Exp. Med. 210: 1079-1086.
13. Häcker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Häcker, et al. 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204-207.
14. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar, A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptordependent and -independent antiviral response. Nature 439: 208-211.
15. Rub, A., R. Dey, M. Jadhav, R. Kamat, S. Chakkaramakkil, S. Majumdar, R. Mukhopadhyaya, and B. Saha. 2009. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat. Immunol. 10: 273-280.
16. Clausen, B. E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Förster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8: 265-277.
17. Clemens, R. A., L. E. Lenox, T. Kambayashi, N. Bezman, J. S. Maltzman, K. E. Nichols, and G. A. Koretzky. 2007. Loss of SLP-76 expression within myeloid cells confers resistance to neutrophil-mediated tissue damage while maintaining effective bacterial killing. J. Immunol. 178: 4606-4614.
18. Zhang, X., R. Goncalves, and D. M. Mosser. 2008. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14: Unit 14.1.
19. Weischenfeldt, J., and B. Porse. 2008. Bone marrow-derived macrophages (BMM): Isolation and applications. CSH Protoc. 2008: Pdb.prot5080.
20. Manzanero, S. 2012. Generation of mouse bone marrow-derived macrophages. Methods Mol. Biol. 844: 177-181.
21. Edwards, S. K., C. R. Moore, Y. Liu, S. Grewal, L. R. Covey, and P. Xie. 2013. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma. BMC Cancer 13: 481.
22. Xie, P., J. Poovassery, L. L. Stunz, S. M. Smith, M. L. Schultz, L. E. Carlin, and G. A. Bishop. 2011. Enhanced Toll-like receptor (TLR) responses of TNFRassociated factor 3 (TRAF3)-deficient B lymphocytes. J. Leukoc. Biol. 90: 1149-1157.
23. Morse, H. C., III, M. R. Anver, T. N. Fredrickson, D. C. Haines, A. W. Harris, N. L. Harris, E. S. Jaffe, S. C. Kogan, I. C. MacLennan, P. K. Pattengale, and J. M. Ward, Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium. 2002. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100: 246-258.
24. Hao, X., T. N. Fredrickson, S. K. Chattopadhyay, W. Han, C. F. Qi, Z. Wang, J. M. Ward, J. W. Hartley, and H. C. Morse, III. 2010. The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyteassociated lymphoma of mice. Vet. Pathol. 47: 434-445.
25. King, C. G., T. Kobayashi, P. J. Cejas, T. Kim, K. Yoon, G. K. Kim, E. Chiffoleau, S. P. Hickman, P. T. Walsh, L. A. Turka, and Y. Choi. 2006. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat. Med. 12: 1088-1092.
26. Fredrickson, T. N., J. W. Hartley, and H. C. Morse, III. 2010. Citrobacterinduced colitis in mice with murine acquired immunodeficiency syndrome. Vet. Pathol. 47: 312-317.
27. Lin, T. M. 1971. Colonization and encystation of Entamoeba muris in the rat and the mouse. J. Parasitol. 57: 375-382.
28. Cobo, E. R., C. He, K. Hirata, G. Hwang, U. Tran, L. Eckmann, R. L. Gallo, and S. L. Reed. 2012. Entamoeba histolytica induces intestinal cathelicidins but is resistant to cathelicidin-mediated killing. Infect. Immun. 80: 143-149.
29. Dzhagalov, I., A. St John, and Y.W. He. 2007. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 109: 1620-1626.
30. Yang, Y., B. Liu, J. Dai, P. K. Srivastava, D. J. Zammit, L. Lefrancois, and Z. Li. 2007. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 26: 215-226.
31. Beekman, R., and I. P. Touw. 2010. G-CSF and its receptor in myeloid malignancy. Blood 115: 5131-5136.
32. Greenbaum, A. M., and D. C. Link. 2011. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 25: 211-217.
33. Gaffen, S. L. 2011. Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23: 613-619.
34. Das, S., E. Sarrou, S. Podgrabinska, M. Cassella, S. K. Mungamuri, N. Feirt, R. Gordon, C. S. Nagi, Y. Wang, D. Entenberg, et al. 2013. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J. Exp. Med. 210: 1509-1528.
35. Kyriakides, T. R., M. J. Foster, G. E. Keeney, A. Tsai, C. M. Giachelli, I. Clark- Lewis, B. J. Rollins, and P. Bornstein. 2004. The CC chemokine ligand, CCL2/ MCP1, participates in macrophage fusion and foreign body giant cell formation. Am. J. Pathol. 165: 2157-2166.
36. Conti, I., and B. J. Rollins. 2004. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 14: 149-154.
37. Sarafi, M. N., E. A. Garcia-Zepeda, J. A. MacLean, I. F. Charo, and A. D. Luster. 1997. Murine monocyte chemoattractant protein (MCP)-5: A novel CC chemokine that is a structural and functional homologue of human MCP-1. J. Exp. Med. 185: 99-109.
38. Charo, I. F., and W. Peters. 2003. Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation 10: 259-264.
39. Liu, M., S. Guo, J. M. Hibbert, V. Jain, N. Singh, N. O. Wilson, and J. K. Stiles. 2011. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22: 121-130.
40. Liu, M., S. Guo, and J. K. Stiles. 2011. The emerging role of CXCL10 in cancer (Review). Oncol. Lett. 2: 583-589.
41. Sharif, O., and S. Knapp. 2008. From expression to signaling: Roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213: 701-713.
42. Arts, R. J., L. A. Joosten, J. W. van der Meer, and M. G. Netea. 2013. TREM-1: Intracellular signaling pathways and interaction with pattern recognition receptors. J. Leukoc. Biol. 93: 209-215.
43. Jenkinson, S. R., J. A. Williams, H. Jeon, J. Zhang, T. Nitta, I. Ohigashi, M. Kruhlak, S. Zuklys, S. Sharrow, A. Adams, et al. 2013. TRAF3 enforces the requirement for T cell cross-talk in thymic medullary epithelial development. Proc. Natl. Acad. Sci. USA 110: 21107-21112.
44. Xiu, Y., H. Xu, C. Zhao, J. Li, Y. Morita, Z. Yao, L. Xing, and B. F. Boyce. 2014. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J. Clin. Invest. 124: 297-310.
45. Baniyash, M., M. Sade-Feldman, and J. Kanterman. 2014. Chronic inflammation and cancer: Suppressing the suppressors. Cancer Immunol. Immunother. 63: 11-20.
46. Wesolowski, R., J. Markowitz, and W. E. Carson, III. 2013. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J. Immunother. Cancer 1: 10.
47. Brandau, S., K. Moses, and S. Lang. 2013. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins? Semin. Cancer Biol. 23: 171-182.
48. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 182: 4499-4506.
49. Saha, S. K., E. M. Pietras, J. Q. He, J. R. Kang, S. Y. Liu, G. Oganesyan, A. Shahangian, B. Zarnegar, T. L. Shiba, Y. Wang, and G. Cheng. 2006. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J. 25: 3257-3263.
50. Watanabe, T., N. Asano, S. Fichtner-Feigl, P. L. Gorelick, Y. Tsuji, Y. Matsumoto, T. Chiba, I. J. Fuss, A. Kitani, and W. Strober. 2010. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J. Clin. Invest. 120: 1645-1662.
51. Perkins, D. J., S. K. Polumuri, M. E. Pennini, W. Lai, P. Xie, and S. N. Vogel. 2013. Reprogramming of murine macrophages through TLR2 confers viral resistance via TRAF3-mediated, enhanced interferon production. PLoS Pathog. 9: E1003479.
52. Izcue, A., J. L. Coombes, and F. Powrie. 2009. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27: 313-338.
53. Chow, J., H. Tang, and S. K. Mazmanian. 2011. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr. Opin. Immunol. 23: 473-480.
54. Kamada, N., G. Y. Chen, N. Inohara, and G. Núnez. 2013. Control of pathogens and pathobionts by the gut microbiota. Nat. Immunol. 14: 685-690.
55. Ivory, C. P., M. Prystajecky, C. Jobin, and K. Chadee. 2008. Toll-like receptor 9- dependent macrophage activation by Entamoeba histolytica DNA. Infect. Immun. 76: 289-297.
56. Philpott, D. J., M. T. Sorbara, S. J. Robertson, K. Croitoru, and S. E. Girardin. 2014. NOD proteins: Regulators of inflammation in health and disease. Nat. Rev. Immunol. 14: 9-23.
57. Biswas, A., and K. S. Kobayashi. 2013. Regulation of intestinal microbiota by the NLR protein family. Int. Immunol. 25: 207-214.
58. Buchanan, R. M., B. P. Arulanandam, and D. W. Metzger. 1998. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J. Immunol. 161: 5525-5533.
59. Kopf, M., S. Herren, M. V. Wiles, M. B. Pepys, and M. H. Kosco-Vilbois. 1998. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J. Exp. Med. 188: 1895-1906.
60. Poudrier, J., P. Graber, S. Herren, D. Gretener, G. Elson, C. Berney, J. F. Gauchat, and M. H. Kosco-Vilbois. 1999. A soluble form of IL-13 receptor alpha 1 promotes IgG2a and IgG2b production by murine germinal center B cells. J. Immunol. 163: 1153-1161.
61. Choi, Y. S., D. Eto, J. A. Yang, C. Lao, and S. Crotty. 2013. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J. Immunol. 190: 3049-3053.
62. Sweet, R. A., S. K. Lee, and C. G. Vinuesa. 2012. Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity. Curr. Opin. Immunol. 24: 658-664.
63. Chakarov, S., and N. Fazilleau. 2014. Monocyte-derived dendritic cells promote T follicular helper cell differentiation. EMBO Mol. Med. 6: 590-603.
64. Pratama, A., and C. G. Vinuesa. 2014. Control of TFH cell numbers: Why and how? Immunol. Cell Biol. 92: 40-48.
65. Shaffer, A. L., A. Rosenwald, and L. M. Staudt. 2002. Lymphoid malignancies: The dark side of B-cell differentiation. Nat. Rev. Immunol. 2: 920-932.
66. Kuppers, R., and R. Dalla-Favera. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20: 5580-5594.
67. Peled, J. U., F. L. Kuang, M. D. Iglesias-Ussel, S. Roa, S. L. Kalis, M. F. Goodman, and M. D. Scharff. 2008. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 26: 481-511.
68. Karin, M., T. Lawrence, and V. Nizet. 2006. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835.
69. Mechtcheriakova, D., M. Svoboda, A. Meshcheryakova, and E. Jensen-Jarolim. 2012. Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer. Cancer Immunol. Immunother. 61: 1591-1598.
70. Hasselbalch, H. C. 2013. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk. Res. 37: 214-220.
71. Kamp, D. W., E. Shacter, and S. A. Weitzman. 2011. Chronic inflammation and cancer: The role of the mitochondria. Oncology (Williston Park). 25: 400-410, 413.
72. Rakoff-Nahoum, S., J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R. Medzhitov. 2004. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.
73. Pradere, J. P., D. H. Dapito, and R. F. Schwabe. 2014. The Yin and Yang of Tolllike receptors in cancer. Oncogene 33: 3485-3495.
74. Sato, Y., Y. Goto, N. Narita, and D. S. Hoon. 2009. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2(Suppl. 1): 205-214.
75. Saxena, M., and G. Yeretssian. 2014. NOD-like receptors: Master regulators of inflammation and cancer. Front. Immunol. 5: 327.
76. Wang, J. Q., Y. S. Jeelall, L. L. Ferguson, and K. Horikawa. 2014. Toll-like receptors and cancer: MYD88 mutation and inflammation. Front. Immunol. 5: 367.
77. Allen, I. C., J. E. Wilson, M. Schneider, J. D. Lich, R. A. Roberts, J. C. Arthur, R. M. Woodford, B. K. Davis, J. M. Uronis, H. H. Herfarth, et al. 2012. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kB signaling. Immunity 36: 742-754.
78. Wimmer, N., B. Huber, N. Barabas, J. Röhrl, K. Pfeffer, and T. Hehlgans. 2012. Lymphotoxin b receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J. Immunol. 188: 3426-3433.
79. Hoshi, N., D. Schenten, S. A. Nish, Z. Walther, N. Gagliani, R. A. Flavell, B. Reizis, Z. Shen, J. G. Fox, A. Iwasaki, and R. Medzhitov. 2012. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat. Commun. 3: 1120.
80. Fukata, M., A. Chen, A. S. Vamadevan, J. Cohen, K. Breglio, S. Krishnareddy, D. Hsu, R. Xu, N. Harpaz, A. J. Dannenberg, et al. 2007. Toll-like receptor-4 promotes the development of colitis-Associated colorectal tumors. Gastroenterology 133: 1869-1881.
81. Keats, J. J., R. Fonseca, M. Chesi, R. Schop, A. Baker, W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, et al. 2007. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
82. Annunziata, C. M., R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, et al. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
83. Demchenko, Y. N., O. K. Glebov, A. Zingone, J. J. Keats, P. L. Bergsagel, and W. M. Kuehl. 2010. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115: 3541-3552.
84. Nagel, I., S. Bug, H. Tönnies, O. Ammerpohl, J. Richter, I. Vater, E. Callet- Bauchu, M. J. Calasanz, J. A. Martinez-Climent, C. Bastard, et al. 2009. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14) (q24.1q32.33). Leukemia 23: 2153-2155.
85. Rossi, D., S. Deaglio, D. Dominguez-Sola, S. Rasi, T. Vaisitti, C. Agostinelli, V. Spina, A. Bruscaggin, S. Monti, M. Cerri, et al. 2011. Alteration of BIRC3 and multiple other NF-kB pathway genes in splenic marginal zone lymphoma. Blood 118: 4930-4934.
86. Braggio, E., J. J. Keats, X. Leleu, S. Van Wier, V. H. Jimenez-Zepeda, R. Valdez, R. F. Schop, T. Price-Troska, K. Henderson, A. Sacco, et al. 2009. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 69: 3579-3588.
87. Otto, C., M. Giefing, A. Massow, I. Vater, S. Gesk, M. Schlesner, J. Richter, W. Klapper, M. L. Hansmann, R. Siebert, and R. Kuppers. 2012. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br. J. Haematol. 157: 702-708.
88. Pérez de Diego, R., V. Sancho-Shimizu, L. Lorenzo, A. Puel, S. Plancoulaine, C. Picard, M. Herman, A. Cardon, A. Durandy, J. Bustamante, et al. 2010. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33: 400-411.
89. Momeni, M., N. Zainodini, R. Bidaki, G. Hassanshahi, H. Daneshvar, M. Khaleghinia, M. Ebrahim, M. Karimi-Googheri, A. Askari, M. K. Arababadi, and D. Kennedy. 2014. Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients. Hum. Immunol. 75: 15-19.